Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Identification of the CD4+ T cell as a major pathogenic factor in ischemic acute renal failure
Melissa J. Burne, … , Michael P. O’Donnell, Hamid Rabb
Melissa J. Burne, … , Michael P. O’Donnell, Hamid Rabb
Published November 1, 2001
Citation Information: J Clin Invest. 2001;108(9):1283-1290. https://doi.org/10.1172/JCI12080.
View: Text | PDF
Article

Identification of the CD4+ T cell as a major pathogenic factor in ischemic acute renal failure

  • Text
  • PDF
Abstract

Leukocytes have been implicated in the pathogenesis of ischemic acute renal failure (ARF), but the roles of the individual cell types involved are largely unknown. Recent indirect evidence suggests that T cells may play an important role in a murine model of ARF. In the current study, we found that mice deficient in T cells (nu/nu mice) are both functionally and structurally protected from postischemic renal injury. Reconstitution of nu/nu mice with wild-type T cells restored postischemic injury. We then analyzed the contribution of the individual T cell subsets to postischemic injury and found that mice deficient in CD4+ T cells, but not mice deficient in CD8+ T cells, were significantly protected from ARF. Direct evidence for a pathophysiologic role of the CD4+ T cell was obtained when reconstitution of CD4-deficient mice with wild-type CD4+ T cells restored postischemic injury. In addition, adoptive transfers of CD4+ T cells lacking either the costimulatory molecule CD28 or the ability to produce IFN-γ were inadequate to restore injury phenotype. These results demonstrate that the CD4+ T cell is an important mediator of ischemic ARF, and targeting this cell may yield novel therapies.

Authors

Melissa J. Burne, Frank Daniels, Asmaa El Ghandour, Shamila Mauiyyedi, Robert B. Colvin, Michael P. O’Donnell, Hamid Rabb

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Flow cytometry confirmation of the absence or presence of CD4+ and/or CD...
Flow cytometry confirmation of the absence or presence of CD4+ and/or CD8+ T cells. (a) CD4+ and CD8+ T cells are absent from spleens obtained from nu/nu mice. (b) After nu/nu mice were adoptively transferred with a T cell population from a wild-type control mouse, both CD4+ and CD8+ T cells were detected in spleens. The reconstitution of these cells in nu/nu mice ranged between 2 and 6%. (c) CD4-deficient mice show an absence of CD4+ T cells, but a normal complement of CD8+ T cells when compared with a wild-type control (not shown). (d) CD4-reconstituted CD4-deficient mice show a CD4+ population of approximately 2%.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts